
RadNet has acquired ultrasound AI vendor See-Mode Technologies, aiming to enhance workflow efficiency and expand its imaging AI offerings.
Key Details
- 1RadNet completed the acquisition of See-Mode Technologies, an AI company focused on breast and thyroid ultrasound analysis.
- 2See-Mode's FDA-cleared thyroid solution is already deployed at some RadNet outpatient centers, showing a 30% reduction in scan times.
- 3Approximately 20 million ultrasound exams for thyroid and breast are performed annually in the US, highlighting a large addressable market.
- 4RadNet plans to integrate See-Mode’s products into its DeepHealth AI portfolio and market them to third parties.
- 5The deal follows earlier acquisitions of iCAD, Quantib, Aidence, and Kheiron by RadNet, further bolstering their AI division.
- 6Financial terms of the acquisition were not disclosed.
Why It Matters

Source
Radiology Business
Related News

FDA Expands Clearance for AI-Guided Echo Exams on Existing Ultrasound Systems
FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.

NVIDIA Envisions Autonomous AI Agents Transforming Radiology
NVIDIA foresees a major shift in radiology toward autonomous AI agents and imaging systems that could revolutionize patient care.

AI Ultrasound Tool May Cut Unnecessary Breast Biopsies by 60%
An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.